ACST, I did see this when they announced there fins back in July. They always are but wth.
Top-line results for the recently completed TRIFECTA and PK trial are expected by the end of September 2014, with full data for both trials coming out in the following quarter. Top-line data for the TRIFECTA trial will include the efficacy of CaPre(R) in lowering triglycerides, along with its impact on other lipid markers, including high-density lipoprotein (HDL) and non-HDL as well as low-density lipoprotein (LDL).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.